<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3346/jkms.2008.23.1.89</article-id><article-id pub-id-type="pmid">18303205</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Interleukin-10 and Tumor Necrosis Factor-&#x003b1; Polymorphisms in Vascular Access Failure in Patients on Hemodialysis: Preliminary Data in Korea</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sung</surname><given-names>Su Ah</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Gang Jee</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author"><name><surname>Jo</surname><given-names>Sang Kyung</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cho</surname><given-names>Won Yong</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyoung Kyu</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>So Young</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Division of Nephrology, Eulji Hospital, Seoul, Korea.</aff><aff id="A2"><label>*</label>Department of Internal Medicine, Korea University Hospital, Seoul, Korea.</aff><author-notes><corresp> Address for correspondence: Won Yong Cho, M.D. Division of Nephrology, Department of Internal Medicine, Korea University Hospital, 126-1 Anam-dong 5th street, Sungbuk-gu, Seoul 136-705, Korea. Tel: +82.2-920-5599, Fax: +82.2-927-5344, <email>wonyong@korea.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>20</day><month>2</month><year>2008</year></pub-date><volume>23</volume><issue>1</issue><fpage>89</fpage><lpage>93</lpage><history><date date-type="received"><day>06</day><month>12</month><year>2006</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Neointimal hyperplasia causes vascular stenosis and subsequent thrombosis, which result in vascular access failure in patients undergoing hemodialysis. Interleukin-10 (IL-10) and tumour necrosis factor-&#x003b1; (TNF-&#x003b1; ) are involved in this inflammatory process. The aim of this study was to investigate the relationship between vascular accessm failure and various inflammatory markers including the genetic polymorphisms of IL-10 and TNF-&#x003b1; . Seventy-five patients on hemodialysis with an arteriovenous fistula in place or an artificial graft (18 with vascular access failure and 82 without failure) and 98 healthy individuals were genotyped for IL-10 and TNF-&#x003b1; single nucleotide polymorphisms. Clinical and laboratory data including serum IL-10 and TNF-&#x003b1; levels were compared. Stimulated IL-10 levels, from in vitro incubation of blood with lipopolysaccharide, were also obtained and compared. Female gender, hypoproteinemia, and hypertriglyceridemia were associated with vascular access failure. The basal TNF-&#x003b1; level was significantly higher in patients with access failure. The distribution of IL-10 and TNF-&#x003b1; genotype did not differ among patients with or without access failure. This study could not demonstrate a relationship between genetic polymorphisms and vascular access failure. However, an altered immune response and inflammation might contribute to vascular access failure.</p></abstract><kwd-group><kwd>Polymorphism, Single Nucleotide</kwd><kwd>Arteriovenous Shunt, Surgical</kwd><kwd>Constriction, Pathologic</kwd><kwd>Renal Dialysis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Vascular access failure, the most frequent cause of morbidity and hospitalization in patients undergoing hemodialysis, is primarily due to vascular stenosis, which predisposes to thrombosis and subsequently leading to access obstruction. Neointimal hyperplasia (NIH) is believed to be the predominant cause of vascular stenosis of both the arteriovenous fistula and the polytetrafluoroethylene (PTFE) graft (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The pathophysiology of NIH consists of an aberrant wound healing process characterized by vascular smooth muscle cell (VSMC) migration, adherence, proliferation, and extracellular matrix deposition. The altered VSMC response is mediated in part by cytokines and growth factors. Tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) stimulates the synthesis of other pro-inflammatory cytokines and adhesion molecules; it has a chemotactic activity for monocytes and stimulates migration and proliferation of VSMC. Interleukin-10 (IL-10) exerts an anti-inflammatory activity, which inhibits inflammatory cytokines such as TNF-&#x003b1; and inactivates inflammatory cells.</p><p>Inflammatory cytokine genes, or their promoter regions, have single nucleotide polymorphisms that influence the rate and magnitude of cytokine production. Many cytokine gene polymorphisms have been reported to be associated with a predisposition to develop a variety of inflammatory diseases (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). The transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1) gene polymorphisms were reported to influence the risk for arteriovenous fistula failure in patients undergoing hemodialysis (<xref ref-type="bibr" rid="B5">5</xref>). The TNF-&#x003b1; -308 gene polymorphism has been reported to be associated with PTFE graft failure (<xref ref-type="bibr" rid="B3">3</xref>).</p><p>In this study, we examined the relationship between various inflammatory markers and vascular access failure. We also evaluated the influence of TNF-&#x003b1; and IL-10 genetic polymorphisms on the development of vascular access failure.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Patient population</title><p>From January to December 2005, 100 patients on maintenance hemodialysis at the Korea University Anam Hospital were selected for this cross-sectional study. Ninety-eight healthy individuals were recruited from the Medical Examination Center of Korea University Anam Hospital to serve as control. Informed consent was obtained in accordance with the guidelines set forth by the Declaration of Helsinki. Clinical information, laboratory data, and history of vascular accesses of study patients were assessed by a chart review. Vascular access failure was defined as the need for any angioplastic or surgical intervention to correct poorly or non-functioning fistula or graft.</p></sec><sec><title>Single nucleotide gene polymorphisms</title><p>Genomic DNA was prepared from peripheral blood mononuclear cells from patients and from healthy controls using the QIAmp DNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer's specifications. Briefly, 1 mL of whole blood was collected from a patient in a heparinized tube, digested with proteinase-K, and submitted to a silica gel QIAmp spin column. The blood column was washed with appropriated buffers, and the total DNA was eluted with 200 &#x000b5;L of elution buffer. The total DNA recovered from each sample was quantified and assessed for purity by spectrophotometric analysis at 260 and 280 nm.</p><p>Cytokine genotyping for IL-10 (-1,082 G/A) and TNF-&#x003b1; (-308 G/A) was performed using the amplification refractory mutational system method (ARMS-PCR). Briefly, 0.1 &#x000b5;g of total DNA was amplified by PCR in a 10 &#x000b5;L reaction mixture containing 1 &#x000d7; AS reaction buffer, 200 &#x000b5;M deoxynucleotide triphosphate (dNTP), 1.5 mM MgCl<sub>2</sub>, 8.5% sucrose, 0.25 units Thermoprime<sup>PLUS</sup> DNA polymerase, 5 &#x000b5;M specific primer mixture, and 1 &#x000b5;M internal control primer mixture. The primer sets for TNF-&#x003b1; -308 PCR were generic primer 5'-TCTCGGTTTCTTCTCCATCG-3', primer G 5'-ATAGGTTTTGAGGGGCATGG-3', and primer A 5'-AATAGGTTTTGAGGGGCATGA-3'. The primer sets for IL-10 -1,082 PCR are generic primer 5'-CAGTGCCAACTGAGAATTTGG-3', primer G 5'-CTACTAAGGCTTCTTTGGGAG-3', and primer A 5'-ACTACTAAGGCTTCTTTGGGAA-3'.</p></sec><sec><title>Serum cytokine levels</title><p>A peripheral blood sample was obtained in a heparinized bottle prior to hemodialysis and was divided into two wells. One &#x000b5;g/mL of lipopolysaccharide (LPS <italic>E. coli</italic>, Sigma, St Louis, U.S.A.) was added to one well. Samples and controls without LPS were incubated at 37&#x02103;, 5% CO<sub>2</sub> for 24 hr and spun for 15 min, and the serum supernatant aliquots were stored at -20&#x02103; until analyzed. The serum IL-10 level was measured by the quantitative sandwich enzyme- linked immunosorbent assay (Quantikine, RD systems, Minneapolis, U.S.A.) in accordance with the manufacturer's instructions.</p><p>TNF-&#x003b1; was studied on blood samples taken before hemodialysis and allowed to clot; the samples were then spun for 15 min, and the serum supernatant aliquots were frozen at -20&#x02103;. The serum TNF-&#x003b1; level was measured by the same method as above.</p></sec><sec><title>Statistics</title><p>Data management and statistical analysis were done using the SPSS software. The &#x003c7;<sup>2</sup>-test was used to compare the genotype frequencies between healthy control and patient groups. The nonparametric Mann-Whitney-<italic>U</italic> test was used to compare continuous data including serum cytokine levels between patients with or without vascular access failure. The Kruskal-Wallis test was used for comparisons between healthy control and two patient groups. A <italic>p</italic> value &#x0003c;0.05 was considered as significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patient characteristics</title><p>Eighteen among 100 patients had vascular access failure. Comparisons of baseline characteristics among the patients are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The patients on hemodialysis were much older than the healthy control group. The proportion of female and the proportion of PTFE graft were higher in the vascular access failure group than the good functioning access group. The prevalence of diabetes and hypertension, and duration of hemodialysis and vascular access were not different between patients with or without vascular access failure. Hypoproteinemia and hypertriglyceridemia were much more frequent among the patients with vascular access failure (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec><title>Distribution of cytokine genotype polymorphisms</title><p>The distribution of genotypes were 40% AA, 48% AG, 12% GG for -1,082 IL-10, and 8% AA, 40% AG, 52% GG for -308 TNF-&#x003b1;. There was no difference in genotype frequencies between the patients with vascular access failure and those with good functioning access (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p></sec><sec><title>Serum cytokine levels</title><p>Although the patients on hemodialysis produced a higher level of LPS-stimulated IL-10 than healthy controls, no significant differences were revealed among the patients with or without access failure. Patients genotyped as A negative at -1,082 IL-10 showed a higher level of LPS-stimulated IL-10 level, GG&#x0003e;AG&#x0003e;AA (<xref ref-type="fig" rid="F2">Fig. 2</xref>). There was no significant difference in basal IL-10 levels.</p><p>Basal TNF-&#x003b1; was much higher in the vascular access failure group compared to the good functioning access group (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Patients with AG at -308 TNF-&#x003b1; exhibited a significantly higher level of basal TNF-&#x003b1; than GG or AA.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>An aberrant wound healing process in response to chemical or mechanical injury is believed to explain the pathophysiology of NIH; VSMC proliferates and migrates into the intima of vessels, where they induce intimal expansion via extracellular matrix deposition. Although it is not clear whether the fibroproliferative response occurs by way of inflammatory pathways or whether the inflammation is secondary to other driving mechanisms, several studies have suggested that inflammatory cytokines play a critical role in NIH. TNF-&#x003b1;, a proximal inflammatory cytokine, stimulates the expression of adhesion molecules and other pro-inflammatory cytokines including platelet-derived growth factor (PDGF) and TGF-&#x003b2; 1, which are important mediators of VSMC proliferation and migration (<xref ref-type="bibr" rid="B6">6</xref>). The TNF-&#x003b1; level was shown to increase for several days prior to migration of VSMC into the intima, in balloon-injured rat aorta; the TNF-&#x003b1; antagonist-inhibited coronary artery NIH in cholesterol-fed rabbits after cardiac transplantation (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). IL-10 exerts anti-inflammatory activities directed against the function of inflammatory cells, and inhibits the production of inflammatory cytokines, such as TNF-&#x003b1; , IL-1, and IL-8. IL-10 was shown to interfere with NIH, after balloon injury or stent implantation, in hypercholesterolemic rabbits, and potently abrogates the proliferative response to atherogenic mitogens (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>).</p><p>The critical role of TNF-&#x003b1; and IL-10 in NIH and the functional relevance of the single nucleotide polymorphism suggest a relationship between TNF-&#x003b1; and IL-10 gene polymorphisms and vascular access failure in patients on hemodialysis. Single nucleotide polymorphisms, located in the promoter regions of the TNF-&#x003b1; gene -308 and the IL-10 -1,082, have been found to differentially affect binding of nuclear transcription factors, transcriptional activity, and protein production (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>). Expression of the A allele in -308 TNF-&#x003b1; gene results in increased genetic transcription and subsequent production of TNF-&#x003b1; compared to the normal production by the genotype GG, and the presence of the A allele is associated with increased mortality in diabetic patients (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). The TNF-&#x003b1; -308 gene polymorphism has been reported to be associated with PTFE graft failure (<xref ref-type="bibr" rid="B3">3</xref>). However, based on our results, the functionally relevant single nucleotide polymorphisms of the genes encoding TNF-&#x003b1; and IL-10 did not correlate with vascular access failure. These negative results should not be interpreted as an argument against the importance of inflammatory responses elicited in vascular access failure and the critical role of TNF-&#x003b1; and IL-10 as regulators. Instead, apparent lack of association may reflect the complexity of interactions underlying the NIH and subsequent vascular stenosis, and may also largely be attributable to the inadequate sample size available for our study. In fact, previous studies on the IL-10 -1,082 polymorphism have not always revealed a relationship with inflammatory disease. A relationship was not demonstrated in coronary artery restenosis after angioplasty (<xref ref-type="bibr" rid="B14">14</xref>), rheumatoid arth- ritis and chronic hepatitis (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>), development of cervical cancer (<xref ref-type="bibr" rid="B17">17</xref>), and prognosis of lymphoma and breast cancer (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>).</p><p>In addition to the small sample size, there were other limitations in this study. The patients examined in this study were all Koreans, and different results may be obtained with populations of other ethnic origins. The distribution of genetic polymorphisms of the IL-10 -1,082 and TNF-&#x003b1; -308 differ in Caucasian populations (<xref ref-type="bibr" rid="B20">20</xref>). We did not compare the diameter of the access vessels, an important factor for the development of vascular access failure (<xref ref-type="bibr" rid="B21">21</xref>). Lastly, we did not measure the stimulated TNF-&#x003b1; level.</p><p>The results showed that female gender, hypoproteinemia, and hypertriglyceridemia were associated with vascular access failure. This is in agreement with previous reports (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Female patients may have vessels of smaller diameter. Ernandez et al. reported that female gender appears to be an independent risk factor for early failure of AVF when adjusted for initial artery diameter (<xref ref-type="bibr" rid="B21">21</xref>). Hypoproteinemia, as a result of inflammation, might be related with vascular access failure. Inflammation decreases the synthesis of protein in liver, and is associated with a greater fractional catabolic rate and, when extreme, increases the transfer of albumin out of the vascular compartment. A vicious cascade of events ensues in which inflammation induces anorexia and reduces the effective use of dietary protein and energy intake and augments catabolism of protein. De Marchi et al. reported that a high total cholesterol/HDL cholesterol ratio and hypertriglyceridemia are powerful risk indicators for fistula obstruction of patients on hemodialysis (<xref ref-type="bibr" rid="B22">22</xref>).</p><p>In conclusion, this cross-sectional study did not reveal a relationship between vascular access failure and single nucleotide polymorphisms of IL-10 -1,082 and TNF-&#x003b1; -308. However, female gender, hypoproteinemia, and hypertriglyceridemia could be risk factors for the development of access failure, and the imbalance of cytokine networks including TNF-&#x003b1; from uremia could have influenced the development of access failure. Further prospective studies involving a large study population should follow to inrolentify factors that are useful in detection of risk factors for access failure to improve the management of patients on hemodialysis.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rekhter</surname><given-names>M</given-names></name><name><surname>Nicholls</surname><given-names>S</given-names></name><name><surname>Ferguson</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name></person-group><article-title>Cell proliferation in human arteriovenous fistulas used for hemodialysis</article-title><source>Arterioscler Thromb</source><year>1993</year><volume>13</volume><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">8096766</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy-Chaudhury</surname><given-names>P</given-names></name><name><surname>Kelly</surname><given-names>BS</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Reaves</surname><given-names>A</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Nanayakkara</surname><given-names>N</given-names></name><name><surname>Heffelfinger</surname><given-names>SC</given-names></name></person-group><article-title>Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts</article-title><source>Kidney Int</source><year>2001</year><volume>59</volume><fpage>2325</fpage><lpage>2334</lpage><pub-id pub-id-type="pmid">11380837</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram</surname><given-names>S</given-names></name><name><surname>Bass</surname><given-names>K</given-names></name><name><surname>Abreo</surname><given-names>K</given-names></name><name><surname>Baier</surname><given-names>RJ</given-names></name><name><surname>Kruger</surname><given-names>TE</given-names></name></person-group><article-title>Tumor necrosis factor-alpha -308 gene polymorphism is associated with synthetic hemodialysis graft failure</article-title><source>J Investig Med</source><year>2003</year><volume>51</volume><fpage>19</fpage><lpage>26</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>K</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name></person-group><article-title>Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction</article-title><source>Nat Genet</source><year>2002</year><volume>32</volume><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">12426569</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heine</surname><given-names>GH</given-names></name><name><surname>Ulrich</surname><given-names>C</given-names></name><name><surname>Sester</surname><given-names>U</given-names></name><name><surname>Sester</surname><given-names>M</given-names></name><name><surname>Kohler</surname><given-names>H</given-names></name><name><surname>Girndt</surname><given-names>M</given-names></name></person-group><article-title>Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients</article-title><source>Kidney Int</source><year>2003</year><volume>64</volume><fpage>1101</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">12911563</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemson</surname><given-names>MS</given-names></name><name><surname>Tordoir</surname><given-names>JH</given-names></name><name><surname>Daemen</surname><given-names>MJ</given-names></name><name><surname>Kitslaar</surname><given-names>PJ</given-names></name></person-group><article-title>Intimal hyperplasia in vascular grafts</article-title><source>Eur J Vasc Endovasc Surg</source><year>2000</year><volume>19</volume><fpage>336</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">10801366</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rus</surname><given-names>HG</given-names></name><name><surname>Niculescu</surname><given-names>F</given-names></name><name><surname>Vlaicu</surname><given-names>R</given-names></name></person-group><article-title>Tumor necrosis factor-alpha in human arterial wall with atherosclerosis</article-title><source>Atherosclerosis</source><year>1991</year><volume>89</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">1793452</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausell</surname><given-names>N</given-names></name><name><surname>Molossi</surname><given-names>S</given-names></name><name><surname>Sett</surname><given-names>S</given-names></name><name><surname>Rabinovitch</surname><given-names>M</given-names></name></person-group><article-title>In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation</article-title><source>Circulation</source><year>1994</year><volume>89</volume><fpage>2768</fpage><lpage>2779</lpage><pub-id pub-id-type="pmid">8205691</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>LJ</given-names></name><name><surname>Aguirre</surname><given-names>L</given-names></name><name><surname>Ziol</surname><given-names>M</given-names></name><name><surname>Bridou</surname><given-names>JP</given-names></name><name><surname>Nevo</surname><given-names>N</given-names></name><name><surname>Michel</surname><given-names>JB</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name></person-group><article-title>Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>908</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">10694531</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>LE</given-names></name><name><surname>Wood</surname><given-names>NA</given-names></name><name><surname>Gillespie</surname><given-names>KM</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name><name><surname>Gaston</surname><given-names>K</given-names></name><name><surname>Mathieson</surname><given-names>PW</given-names></name></person-group><article-title>The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance</article-title><source>Cell Mol Life Sci</source><year>2002</year><volume>59</volume><fpage>560</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">11964134</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Genetics of atopy and asthma: the rationale behind promoter-based candidate gene studies (IL-4 and IL-10)</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><fpage>S152</fpage><lpage>S155</lpage><pub-id pub-id-type="pmid">9351597</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Symons</surname><given-names>JA</given-names></name><name><surname>McDowell</surname><given-names>TL</given-names></name><name><surname>McDevitt</surname><given-names>HO</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><article-title>Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3195</fpage><lpage>3199</lpage><pub-id pub-id-type="pmid">9096369</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haukim</surname><given-names>N</given-names></name><name><surname>Bidwell</surname><given-names>JL</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Keen</surname><given-names>LJ</given-names></name><name><surname>Gallagher</surname><given-names>G</given-names></name><name><surname>Kimberly</surname><given-names>R</given-names></name><name><surname>Huizinga</surname><given-names>T</given-names></name><name><surname>McDermott</surname><given-names>MF</given-names></name><name><surname>Oksenberg</surname><given-names>J</given-names></name><name><surname>McNicholl</surname><given-names>J</given-names></name><name><surname>Pociot</surname><given-names>F</given-names></name><name><surname>Hardt</surname><given-names>C</given-names></name><name><surname>D'Alfonso</surname><given-names>S</given-names></name></person-group><article-title>Cytokine gene polymorphism in human disease: on-line databases, supplement 2</article-title><source>Genes Immun</source><year>2002</year><volume>3</volume><fpage>313</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">12209358</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>W</given-names></name><name><surname>Tiroch</surname><given-names>K</given-names></name><name><surname>von Beckerath</surname><given-names>N</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name></person-group><article-title>Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting</article-title><source>Cytokine</source><year>2003</year><volume>24</volume><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">14572794</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>A</given-names></name><name><surname>Kurzawski</surname><given-names>M</given-names></name><name><surname>Szklarz</surname><given-names>BG</given-names></name><name><surname>Herczynska</surname><given-names>M</given-names></name><name><surname>Drozdzik</surname><given-names>M</given-names></name></person-group><article-title>Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis</article-title><source>Clin Rheumatol</source><year>2005</year><volume>24</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">15915323</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>WG</given-names></name><name><surname>Rigopoulou</surname><given-names>E</given-names></name><name><surname>Haigh</surname><given-names>P</given-names></name><name><surname>Cooksley</surname><given-names>H</given-names></name><name><surname>Mullerova</surname><given-names>I</given-names></name><name><surname>Novelli</surname><given-names>M</given-names></name><name><surname>Winstanley</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Naoumov</surname><given-names>NV</given-names></name></person-group><article-title>Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus</article-title><source>Liver Int</source><year>2004</year><volume>24</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">15078471</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoodsma</surname><given-names>M</given-names></name><name><surname>Nolte</surname><given-names>IM</given-names></name><name><surname>Schipper</surname><given-names>M</given-names></name><name><surname>Oosterom</surname><given-names>E</given-names></name><name><surname>van der Steege</surname><given-names>G</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><name><surname>Te Meerman</surname><given-names>GJ</given-names></name><name><surname>van der Zee</surname><given-names>AG</given-names></name></person-group><article-title>Interleukin-10 and Fas polymorphisms and susceptibility for (pre) neoplastic cervical disease</article-title><source>Int J Gynecol Cancer</source><year>2005</year><volume>15</volume><issue>Suppl 3</issue><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">16343245</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berglund</surname><given-names>M</given-names></name><name><surname>Thunberg</surname><given-names>U</given-names></name><name><surname>Roos</surname><given-names>G</given-names></name><name><surname>Rosenquist</surname><given-names>R</given-names></name><name><surname>Enblad</surname><given-names>G</given-names></name></person-group><article-title>The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>4894</fpage><lpage>4895</lpage><pub-id pub-id-type="pmid">15933064</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JM</given-names></name><name><surname>Bensen-Kennedy</surname><given-names>D</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Thoburn</surname><given-names>CJ</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Vogelsang</surname><given-names>GB</given-names></name><name><surname>Hess</surname><given-names>AD</given-names></name></person-group><article-title>The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer</article-title><source>Biol Blood Marrow Transplant</source><year>2005</year><volume>11</volume><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">15931634</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynard</surname><given-names>MP</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Navarrete</surname><given-names>CV</given-names></name></person-group><article-title>Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK</article-title><source>Eur J Immunogenet</source><year>2000</year><volume>27</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">10998089</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernandez</surname><given-names>T</given-names></name><name><surname>Saudan</surname><given-names>P</given-names></name><name><surname>Berney</surname><given-names>T</given-names></name><name><surname>Merminod</surname><given-names>T</given-names></name><name><surname>Bednarkiewicz</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>PY</given-names></name></person-group><article-title>Risk Factors for Early Failure of Native Arteriovenous Fistulas</article-title><source>Nephron Clin Pract</source><year>2005</year><volume>101</volume><fpage>c39</fpage><lpage>c44</lpage><pub-id pub-id-type="pmid">15886495</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Marchi</surname><given-names>S</given-names></name><name><surname>Falleti</surname><given-names>E</given-names></name><name><surname>Giacomello</surname><given-names>R</given-names></name><name><surname>Stel</surname><given-names>G</given-names></name><name><surname>Cecchin</surname><given-names>E</given-names></name><name><surname>Sepiacci</surname><given-names>G</given-names></name><name><surname>Bortolotti</surname><given-names>N</given-names></name><name><surname>Zanello</surname><given-names>F</given-names></name><name><surname>Gonano</surname><given-names>F</given-names></name><name><surname>Bartoli</surname><given-names>E</given-names></name></person-group><article-title>Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><fpage>1169</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">8866409</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Comparison between percentage frequencies of interleukin-10 and tumour necrosis factor-&#x003b1; genotypes in healthy controls, good functioning access groups and access failure group.</p></caption><graphic xlink:href="jkms-23-89-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Comparison between interleukin-10 single nucleotide polymorphisms in in vitro production of interleukin-10 protein in peripheral blood mononuclear cells after stimulating with lipopolysaccharide.</p></caption><graphic xlink:href="jkms-23-89-g002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>Comparison of the serum tumour necrosis factor-&#x003b1; level between the good functioning access group and the access failure group.</p></caption><graphic xlink:href="jkms-23-89-g003"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparisons of baseline characteristics among the patients</p></caption><graphic xlink:href="jkms-23-89-i001"/><table-wrap-foot><fn><p><sup>*</sup>A <italic>p</italic> value was less than 0.05 compared to the good access group; <sup>&#x02020;</sup>A <italic>p</italic> value was less than 0.05 compared to patients group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparisons of laboratory results between good access and access failure groups</p></caption><graphic xlink:href="jkms-23-89-i002"/><table-wrap-foot><fn><p>WBC, white blood cell; TIBC, total iron-binding capacity; BUN, blood urea nitrogen; CRP, C-reactive protein.</p></fn></table-wrap-foot></table-wrap></floats-group></article>